- Home
- ITHA vs EOLS Comparison
ITHA vs EOLS Comparison
Compare ITHA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITHA | EOLS |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.4M | 284.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ITHA | EOLS |
|---|---|---|
| Price | $9.91 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 22.5K | ★ 757.7K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $9.86 | $3.86 |
| 52 Week High | $9.96 | $12.28 |
Technical Indicators
Market Signals| Indicator | ITHA | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 52.60 |
| Support Level | $9.89 | $4.10 |
| Resistance Level | $9.96 | $4.99 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 58.82 | 87.18 |
Price Performance
Historical ComparisonAbout ITHA ITHAX Acquisition Corp III Class A Ordinary Shares
ITHAX Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.